Xiaoqiao Liu
Overview
Explore the profile of Xiaoqiao Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong J, Cho H, Sa J, Liu X, Ha S, Lee T, et al.
Genome Med
. 2022 Jan;
14(1):1.
PMID: 34986867
Background: A limited number of studies have characterized genomic properties of hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy. Methods: Herein, we performed comprehensive molecular characterization of immediate (D-42...
2.
Chhibber A, Huang L, Zhang H, Xu J, Cristescu R, Liu X, et al.
Immunity
. 2022 Jan;
55(1):56-64.e4.
PMID: 34986342
We evaluated the impact of class I and class II human leukocyte antigen (HLA) genotypes, heterozygosity, and diversity on the efficacy of pembrolizumab. Seventeen pembrolizumab clinical trials across eight tumor...
3.
Liu X, Choi M, Kim K, Kim K, Kim S, Park S, et al.
Pathol Res Pract
. 2020 Feb;
216(4):152881.
PMID: 32089413
Background: The programmed death receptor ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay is a widely used selection method for pembrolizumab treatment in gastric cancer (GC) patients, especially in the...
4.
Pang J, Wu Q, Zhang Z, Zheng T, Xiang Q, Zhang P, et al.
Int J Cardiol Heart Vasc
. 2019 Jul;
23:100317.
PMID: 31321282
Background: Controversy still exists that whether clopidogrel should add proton pump inhibitors (PPIs) in patients with coronary heart disease after percutaneous coronary intervention (PCI). The aim of this study was...
5.
Liu X, Tan H, Liu X, Wu Q
Exp Ther Med
. 2018 Mar;
15(4):3892-3898.
PMID: 29563985
The objective of this study was to investigate the expression level of dynamin-related protein 1 (Drp1) in vascular endothelium of hypertension rats and its correlation with expression of inflammatory factors....
6.
Zhang L, Li S, Choi Y, Lee J, Gong Z, Liu X, et al.
Lung Cancer
. 2017 Jun;
109:21-27.
PMID: 28577945
Objectives: Lung adenocarcinoma (LUAD) is a common subtype of non-small cell lung cancer prevalent in Asia. There is a dearth of understanding regarding the transcriptome landscape of LUAD without primary...
7.
Li S, Choi Y, Gong Z, Liu X, Lira M, Kan Z, et al.
J Thorac Oncol
. 2016 Sep;
11(12):2129-2140.
PMID: 27615396
Introduction: The incidence rate of lung adenocarcinoma (LUAD), the predominant histological subtype of lung cancer, is elevated in Asians, particularly in female nonsmokers. The mutation patterns in LUAD in Asians...
8.
Zhang L, Liu X, Zhang X, Chen R
Mol Genet Genomics
. 2015 Dec;
291(3):1035-51.
PMID: 26711644
Hepatocellular carcinoma (HCC) is an aggressive and deadly cancer. The molecular pathogenesis of the disease remains poorly understood. To better understand HCC biology and explore potential biomarkers and therapeutic targets,...
9.
Zhao G, Li Q, Wang I, Liu X, Fang X, Zhang X
Pharmacogenomics
. 2015 Nov;
16(16):1769-79.
PMID: 26554622
Aim: To develop an analytic method for identifying tissue-specific (TS) genes from RNA-seq data. Materials & Methods: Based on a negative binomial distribution, we develop a statistical method containing consecutive...
10.
Kang L, Liu X, Gong Z, Zheng H, Wang J, Li Y, et al.
Genomics
. 2014 Dec;
105(2):76-82.
PMID: 25462863
We did whole-transcriptome sequencing and whole-genome sequencing on nine pairs of Hepatocellular carcinoma (HCC) tumors and matched adjacent tissues to identify RNA editing events. We identified mean 26,982 editing sites...